Latest news

CardiNor AS and its partners Bioventix Ltd, Kaivogen Oy and Akershus University hospital have been granted Eurostars funding of the project: Secretoneurin, a breakthrough blood biomarker for heart disease and Sudden Cardiac Arrest risk. The total funding by EU is € 631,000. The Eurostars project will support the following important milestones for the company: Development and optimization of a simple test for measuring SN in the blood – Clinical validation using a very comprehensive patient material, this will also support and facilitate future CE marking – Optimization  of assay production that will enable rapid commercialization.

In the media

Unicard, 17.11.2016: (secretoneurin predicts mortality in patients with acute respiratory failure. Article in Norwegian)

Secretoneurin forutsier død ved akutt respirasjonssvikt

Scientific Nordic, 02.10.2015:

Peptide found that predicts heart failure

Unicard, 12.03.2015:

Blodprøve kan fange opp risikopasienter ved hjertesvikt

VG, 27.09.2015:

Dette stoffet kan forutsi hjertedød.


Poster accepted for presentation at European Society of Cardiology annual meeting in Munich on 28th of august. Low concentrations of circulating secretoneurin predict a favourable prognosis after cardiac surgery

Contact Us

Send us an email and we'll get back to you, asap.